The content of this website is intended for United States audiences only.
LAST UPDATED
February 06 2024
Clinicaltrials.gov ID
EudraCT ID
A Phase 2/3 Single-Arm, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734™) in Participants From Birth to < 18 Years of Age With COVID-19 (CARAVAN)
The goals of this clinical study are to learn more about the study drug, remdesivir, and how safe it is in participants less than 18 years old with coronavirus disease 2019 (COVID-19).
View MoreAge
0 - 18 Years
Sex
ALL
Healthy Volunteers
No
Medical Condition
COVID-19
Gender
N/A
Date
July 2020 - February 2023
Study Type
INTERVENTIONAL
Study Phase
PHASE2, PHASE3
Product
Remdesivir
Birmingham, Alabama, United States, 35233
Los Angeles, California, United States, 90027
Los Angeles, California, United States, 90095
Madera, California, United States, 93636
Sacramento, California, United States, 95817
San Diego, California, United States, 92123
Tampa, Florida, United States, 33606
Chicago, Illinois, United States, 60611
Louisville, Kentucky, United States, 40202
New Orleans, Louisiana, United States, 70112
Baltimore, Maryland, United States, 21287
Boston, Massachusetts, United States, 02115
Grand Rapids, Michigan, United States, 49503
Minneapolis, Minnesota, United States, 55404
Bronx, New York, United States, 10461
Bronx, New York, United States, 10467
New Hyde Park, New York, United States, 11040
Charlotte, North Carolina, United States, 28203
Allentown, Pennsylvania, United States, 18103
Philadelphia, Pennsylvania, United States, 19134
Dallas, Texas, United States, 75235
Houston, Texas, United States, 77030
Florence, Italy, 50139
Padova, Italy, 35128
Parma, Italy, 43126
Barcelona, Spain, 8035
Esplugues de llobregat, Spain, 8950
Madrid, Spain, 28009
Madrid, Spain, 28041
Madrid, Spain, 28041
Santiago de Compostela, Spain, 15706
Liverpool, United Kingdom, L12 2AP
Share Trial